News | Myriad Genetics

Illumina and Myriad Genetics expand partnership to broaden access to HRD testing in the United States

Products

Myriad Genetics Reports Fourth Quarter Financial Results; Fourth Quarter Revenue of $177.8 Million Grew 11% Year-Over-Year Driven by 16% Growth in Hereditary Cancer Volumes and 23% Growth in GeneSight® Volumes

Financial

Myriad Genetics to Release Fourth-Quarter Financial Results on Feb. 28, 2023

Financial

Myriad Genetics to Participate in Upcoming Healthcare Conferences

Financial

Myriad Genetics to Present at 41st Annual J.P. Morgan Healthcare Conference

Corporate

Myriad Genetics Hires Five Senior Leaders to Advance Commercial Growth Plans

Corporate

Myriad Genetics to Present New Data at San Antonio Breast Cancer Symposium Showcasing Advancements in Breast Cancer Risk Assessment and Treatment

Products

Myriad Genetics Expands Board of Directors with Election of Paul M. Bisaro as New Board Member

Corporate

Family Cancer History Still a Mystery to Many Women, Myriad Genetics Survey Finds

Corporate

Myriad Genetics Issues Inaugural Environmental, Social and Governance Report

Corporate

Myriad Genetics CEO Paul Diaz to Speak at Goldman Sachs 43rd Annual Global Healthcare Conference

Corporate

Myriad Genetics Showcases Advancements in Precision Medicine with Recent Oncology Portfolio Expansion and New Data Presentations at ASCO 2022

Corporate

Myriad Genetics CEO Paul Diaz to Speak at Bank of America Securities 2022 Healthcare Conference

Corporate

Myriad Genetics Expands Partnership with Intermountain Precision Genomics to Add Liquid Biopsy Therapy Selection Offering to Portfolio of Precise™ Oncology Solutions

Pipeline

Myriad Genetics to Release First-Quarter 2022 Financial Results on May 5, 2022

Financial